Defining novel mechanisms of tumor progression and novel therapeutic targets for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
type: Distribution
access URL: https://theses.hal.science/tel-00987973
format: HTML
issued: 2026-05-05T11:57:13.990136
modified: 2026-05-05T11:57:13.976320

test_moissonnage_selune
type: Agent

Defining novel mechanisms of tumor progression and novel therapeutic targets for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
type: Dataset
contact point: Organization
  fn: CCSD
keyword: tumor-progression
keyword: sdvmheplife-sciences-q-biohuman-health-and-pathology
keyword: semaphorine
keyword: gastroenteropancreatic-neuroendocrine-tumors
keyword: semaphorin
keyword: progression-tumorale
keyword: tumeurs-neuroendocrines-gastroenteropancreatiques
keyword: mtor
keyword: theses
keyword: infoeu-reposemanticsdoctoralthesis
landing page: https://theses.hal.science/tel-00987973
description: GEP-NETs are heterogeneous tumors for which therapeutic options are limited and must therefore be enlarged. Targeted therapies, and mainly everolimus-directed mTOR inhibition, constitute standard treatments for GEP-NETs of pancreatic origin. Nevertheless, the therapeutic benefits of everolimus have not been evaluated in the poorly-differentiated GEP neuroendocrine carcinomas (pdGEP-NECs) subgroup. By using a preclinical in vivo model, we demonstrated that mTOR inhibition could be considered as a therapeutic option for pdGEP-NECs. Then, a proteomic study highlighted novel proteins involved in GEP-NETs progression with all identified factors displaying function in cytoskeleton regulation. Among them, CRMP2 is a key member of class 3 semaphorin (sema3) signaling. An expression profile of sema3 revealed that sema3F expression was decreased in GEP-NETs. The re-expression of this protein in TNE-GEPs cellular models showed that sema3F is responsible of the reduction of cell viability and proliferation. In vivo, sema3F hampered tumor development. Further studies are thus needed to better understand the role of the sema3F signaling pathway in the progression of GEP-NETs
identifier: NNT: 2014LYO10016
issued: 2026-05-05T11:57:13.988629
language: fr
modified: 2026-05-05T11:57:13.988634